Key result
In patients with acute vertebrobasilar artery occlusion undergoing mechanical thrombectomy, adjunctive tirofiban was not associated with an increased risk of symptomatic intracerebral hemorrhage.
Why the study?
Patients with acute vertebrobasilar artery occlusion have high mortality despite mechanical thrombectomy, and the safety and efficacy of adjunctive tirofiban in this setting were unclear.
Does tirofiban improve clinical outcomes or increase bleeding risk in patients with acute vertebrobasilar artery occlusion undergoing mechanical thrombectomy?
Observational (n=130)
Yes
Does tirofiban improve clinical outcomes or increase bleeding risk in patients with acute vertebrobasilar artery occlusion undergoing mechanical thrombectomy?
Adjunctive use of tirofiban during mechanical thrombectomy for acute vertebrobasilar artery occlusion does not appear to improve short- or long-term clinical outcomes or increase the risk of symptomatic intracerebral hemorrhage.
Answers are grounded in this paper and cite their sources.
Tirofiban adjunctive to MT was not associated with better outcomes in AVBAO; leaves open efficacy pending prospective trials.
BACKGROUND: Even undergoing mechanical thrombectomy (MT), patients with acute vertebrobasilar artery occlusion (AVBAO) still have a high rate of mortality. Tirofiban is a novel antiplatelet agent which is now widely empirically used in acute ischemic stroke (AIS). In this study, we aimed to evaluate the safety and efficacy of tirofiban as adjunctive therapy for MT in AVBAO. METHODS: From October 2016 to July 2021, consecutive AVBAO patients receiving MT were included in the prospective stroke registry. The short-term outcomes were (1) symptomatic intracerebral hemorrhage (sICH); (2) in-hospital death; (3) National Institute of Health Stroke Scale (NIHSS) at discharge. The Long-term outcomes were: (1) modified Rankin Scale (mRS) at 3 months; (2) death at 3 months. RESULTS: A total of 130 eligible patients were included in the study, 64 (49.2%) patients received tirofiban. In multivariate regression analysis, no significant differences were observed in all outcomes between the tirofiban and non-tirofiban group [sICH (adjusted OR 0.96; 95% CI, 0.12-7.82, p = 0.97), in-hospital death (adjusted OR 0.57; 95% CI, 0.17-1.89, p = 0.36), NIHSS at discharge (95% CI, -2.14-8.63, p = 0.24), mRS (adjusted OR 1.20; 95% CI, 0.40-3.62, p = 0.75), and death at 3 months (adjusted OR 0.83; 95% CI, 0.24-2.90, p = 0.77)]. CONCLUSIONS: In AVBAO, tirofiban adjunctive to MT was not associated with an increased risk of sICH. Short-term (in-hospital death, NIHSS at discharge) and long-term outcomes (mRS and death at 3 months) seem not to be influenced by tirofiban use.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2022) conducted an observational in Acute vertebrobasilar artery occlusion (n=130). Tirofiban vs. Standard mechanical thrombectomy without tirofiban was evaluated on Symptomatic intracerebral hemorrhage (sICH) (adjusted OR 0.96, 95% CI 0.12-7.82, p=0.97). In patients with acute vertebrobasilar artery occlusion undergoing mechanical thrombectomy, adjunctive tirofiban was not associated with an increased risk of symptomatic intracerebral hemorrhage.
Synapse has enriched 10 related papers. Consider them for comparative context: